Blog

Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers

Photo taken from Agenus/LinkedIn

Aug 9, 2024, 07:16

Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers

Botensilimab is an investigational human Fc-enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies.

Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Recently Agenus announced the publication of a seminal study detailing the novel mechanism of action and effectiveness of botensilimab, an investigational, novel multifunctional anti-CTLA-4 antibody, in various treatment-resistant cancers.

Organizations and Oncologists shared their opinion on it:

Agenus:

“We are pleased to announce the publication of our latest study in Cancer Discovery (AACR Journals) exploring botensilimab’s mechanism of action and potential in addressing various treatment-resistant cancers.”

Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research:

“Now online in Cancer Discovery: Botensilimab, an Fc-enhanced anti-CTLA-4 Antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy – by Dhan Chand and colleagues. ”

Elizabeth McKenna

Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center:

“The Agenus paper on Botensilimab with preclinical data, plus early phase trial with monotherapy and dual combo is on Cancer Discovery: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy.”

Anirban Maitra